NorthWest Biotherapeutics Inc (NWBO)

[DocLee]

George, I am not au fait with the case you mention but if he were part of the trial there would be no alteration to the DCVax-L.

If he had been given DCVax-L on "compassionate" grounds (ie after closure of the DCVax-L Phase 3 study) he probably was treated additionally with poly-ICLC and/or pembrolizumab.

If he was not given DCVax-L he might have been part of Dr. Mulholland's trial at University College, London (UCL) which was investigating whether the addition of ipilimumab (an anti-CTLA monoclonal antibody) to the current Standard of Care (SOL) is beneficial.

Best wishes.